Mallory-denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 10, 2011, Pages

  Rakoski, Mina O ^a   Brown, Morton B ^b   Fontana, Robert J ^a   Bonkovsky, Herbert L ^c,d   Brunt, Elizabeth M ^e   Goodman, Zachary D ^f   Lok, Anna S ^a   Omary, M Bishr ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Cytoplasmic Inclusions; Intermediate Filaments; Keratins; Liver Disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MALLORY BODY; MALLORY DENK BODY; PERICELLULAR FIBROSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STEATOSIS; THROMBOCYTE; TREATMENT OUTCOME;

EID: 80053142481     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.07.006     Document Type: Article

References (24)

1. Zatloukal K., French S.W., Stumptner C., et al. From Mallory to Mallory-Denk bodies: what, how and why?. Exp Cell Res 2007, 313:2033-2049.
2. Omary M.B., Ku N.O., Strnad P., et al. Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest 2009, 119:1794-1805.
3. Hanada S., Strnad P., Brunt E.M., et al. The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology 2008, 48:943-952.
4. Hanada S., Snider N.T., Brunt E.M., et al. Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology 2010, 138:1607-1617.
5. Ku N.O., Gish R., Wright T.L., et al. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med 2001, 344:1580-1587.
6. Ku N.O., Lim J.K., Krams S.M., et al. Keratins as susceptibility genes for end-stage liver disease. Gastroenterology 2005, 129:885-893.
7. Strnad P., Lienau T.C., Tao G.Z., et al. Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 2006, 43:1354-1363.
8. Zhong B., Strnad P., Selmi C., et al. Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology 2009, 50:546-554.
9. Lee W.M., Dienstag J.L., Lindsay K.L., et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004, 25:472-492.
10. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359:2429-2441.
11. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologica 1985, 28:412-419.
12. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
13. Ishak K.G. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994, 7:690-713.
14. Ghany M.G., Lok A.S., Everhart J.E., et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010, 138:136-146.
15. Everhart J.E., Lok A.S., Kim H.Y., et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009, 137:549-557.
16. Lok A.S., Ghany M.G., Goodman Z.D., et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005, 42:282-292.
17. Everson G.T., Hoefs J.C., Seeff L.B., et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44:1675-1684.
18. Brunt E.M. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002, 6:399-420.
19. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
20. Gramlich T., Kleiner D.E., McCullough A.J., et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004, 35:196-199.
21. Cortez-Pinto H., Baptista A., Camilo M.E., et al. Nonalcoholic steatohepatitis-a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 2003, 48:1909-1913.
22. Younossi Z.M., McCullough A.J., Ong J.P., et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004, 38:705-709.
23. Bedossa P., Moucari R., Chelbi E., et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007, 46:380-386.
24. Mohanty S.R., Troy T.N., Huo D., et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009, 50:797-804.